Abstracts study were 1) to determine whether there was an association between drug costs and medical costs for type 1 diabetes patients and, 2) to develop a regression model that predicts medical costs from drug costs. METHODS: The records of 315 patients enrolled in a large mid-western health care plan were reviewed for a 1-year period. The drug costs included insulin costs and oral diabetes drug costs. The medical costs included all paid services for primary and secondary diagnosis of type 1 diabetes identified by ICD-9-CM codes. The data were analyzed using SPSS 10.0. The association between drug and medical costs was determined using Pearson correlation. The significance level was set at the 95% confidence interval. Linear regression analysis was conducted to predict medical costs from drug costs. The dependent variable was the logarithm of medical costs. The independent variables were drug costs, length of service, additional therapy, age and gender. RESULTS: There was a statistically significant inverse correlation between drug costs and medical costs (r = -0.229, CI: -0.33 --0.13). In the regression model the following independent variables were determined to be predictors of medical costs: drug costs (b = 0.00, CI: -0.003 --0.002), additional therapy (b = -0.362, CI: -0.51 --0.21) and length of service (b = 0.002, CI: 0.001 -0.002). Age and gender were not found to be significant predictors of medical costs. CONCLUSIONS: The inverse correlation implies that if type 1 diabetes is managed appropriately with drugs, the medical costs may be reduced. This may reduce the overall health care expenditures. The regression model also showed that as drug costs increased medical costs decreased. The regression model can be used to predict the future medical costs if the drug costs are known.
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A COMPARISON OF TWO METHODS FOR ESTIMATING HEALTH CARE COSTS OF DIABETES
Gause D 1 , Law AW 2 , Singhal PK 3 1 Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA; 2 Duke Clinical Research Institute, Durham, NC, USA; 3 University of Maryland, Baltimore, MD, USA Cost of illness estimates for chronic diseases can be underestimated if only costs related to diagnosis and treatment of that disease are measured. This underestimation results from overlooking costs associated with secondary consequences of the disease such as complications and comorbid conditions associated with the disease. OBJECTIVE: Two methods for estimating medical care costs of diabetes were compared: an "attributable" method" and a "case-control" method. METHODS: The study population was all diabetic patients in the 1999 Medical Expenditure Panel Survey, a nationally representative series of probability surveys on the use and cost of medical care in the United States. "Attributable" costs were estimated by summing costs specifically associated with diabetes. "Case-control" costs were estimated by subtracting costs between diabetic cases and non-diabetic controls which were matched on age, gender, race, and number of comorbid conditions not related to diabetes. Costs were summarized for pharmacy, hospital inpatient, outpatient, and emergency room care and reported in 1999 dollars. RESULTS: The total cost of illness was $3046 per patient using case-control method compared to $1151 per patient using the attributable method. The case-control method found costs to be higher for all categories of care, with the largest being hospital inpatient costs. Cost differences were statistically significant for all categories except for emergency room care. CON-CLUSIONS: Diabetic "attributed" costs accounted for only 39% of the total difference in health care costs between diabetics and matched controls. Patients with diabetes use more medical services than controls, but a large portion of this care is not specifically attributed to diabetes.
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USING LINEAR REGRESSION TO APPROXIMATE RESULTS OF DECISION ANALYSIS: AN APPLICATION TO A COST COMPARISON ACROSS THREE FIRST-LINE DRUG STRATEGIES IN TYPE 2 DIABETES
Botteman MF, Gao X, Stephens JM Abt Associates Clinical Trials, Bethesda, MD, USA OBJECTIVES: Few studies have compared the short-term costs to achieve recommended glycemic goals in Type-2 diabetes. We developed a decision analysis to project costs of treating patients to glycemic goals from a managed care perspective and evaluated feasibility of summarizing this model in an aggregate linear regression (LR) form. METHODS: A literature-based decision model simulated the 3-year treatment costs (medical, pharmacy, adverse events) to achieve an HbA1c < 7% for three cohorts of patients newly diagnosed with Type-2 diabetes and failing lifestyle changes. Each cohort was assigned to a different first-line therapy: glipizide GITS, generic metformin, or rosiglitazone. Add-on treatments occurred as necessary to achieve glycemic control. To summarize the model in a LR form, we first conducted Monte Carlo simulations (MCS) of the model for each therapy. The costs (dependent variables) estimated via 1000 MCS runs were then summarized through OLS regressions, using the most sensitive and/or relevant variables from the decision model as predictors. We then compared the results generated via each method. RESULTS: The projected cost differences between agents with the decision analysis and the aggregate LR form were identical: -$558 (glipizide GITS vs. metformin), -$1557 (glipizide GITS vs. rosiglitazone), and -$998 (metformin vs. rosiglitazone). The R 2 of the LR ranged between .49 and .53. Both methods led to identical conclusions regarding which agent was least/most expensive in >97% of cases. The accordance between projected costs across methods was statistically significant (Kappa > 0.80, p < 0.001) in each head-tohead comparison, confirming the feasibility of using the LR to approximate the results of the decision analysis. CONCLUSIONS: Both methods demonstrate that glipizide GITS is the least expensive first-line therapy for newly diagnosed Type-2 diabetes patients, followed by metformin and rosiglitazone. The LR can be used as a quick and easy tool for use in approximation of the more comprehensive decision tree.
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RESOURCE UTILIZATION USING INNOLET VS. VIAL/SYRINGE FOR DAILY INSULIN INJECTION IN A SUBGROUP OF ELDERLY DIABETIC PATIENTS
Nicklasson L 1 , Lyness W 1 , Liang J 1 , Skovlund S 2 , Lytzen L 2 1 Novo Nordisk Pharmaceuticals Inc, Princeton, NJ, USA; 2 Novo Nordisk A/S, Bagsvaerd, Denmark OBJECTIVE: The goal of this study was to compare resource utilization for two insulin delivery devices: InnoLet® and vial/syringe. METHODS: Diabetic patients requiring assistance with insulin injections (vision and/ or motor impairments) were followed over two 6-week periods in a randomized crossover study to estimate the resource utilization associated with different insulin delivery systems: the InnoLet® insulin doser or the vial and syringe. A total of 79 patients were enrolled in the study. Resource utilization was measured as the number of visits per day which the nurse/caregivers needed to have with the patient in order to assist (if required) with an injection, times the costs for such a visit ($80/hour; minimum visit 1 hour based on local visiting nursing rate) plus the daily cost for insulin. RESULTS: The mean age of patients was 68.2 ± 8.6 years, with a mean A1c level of 7.5 ± 1.4 at baseline. Patients were previously treated with vial/syringe and required assistance with making injections. Reported major hypoglycemic events occurred as frequently with both treatments. The mean daily costs for home visits associated with the injections were $99 and $179 for the InnoLet and vials/syringe patients, respectively (p < 0.001). Fifty-three percent of the patients became independent of nursing/caregiver assistance for the injections when using InnoLet®. Furthermore, the mean time spent by nurses or caregivers for assisting in injection preparation was lower for patients using the InnoLet doser than for the vial and syringe. CONCLU-SIONS: Patients using the InnoLet® doser required significantly fewer visits from nurses/caregivers, resulting in less resource utilization, and use of InnoLet® fostered independence in patients who had difficulty with selfinjection using vial and syringe.
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COST-EFFECTIVENESS ANALYSIS OF GRAFTSKIN (APLIGRAF) AND BECAPLERMIN (REGRANEX) IN DIABETIC NEUROPATHIC FOOT ULCERS
Park J, Hay JW University of Southern California, Los Angeles, CA, USA Becaplermin (Regranex®), a recombinant human platelet-derived growth factor, and graftskin (Apligraf®), a bilayered tissue-engineered human skin equivalent, promote the local wound healing process and therefore reduce the time to complete healing and rate of amputation of lower extremity in diabetic foot ulcer patients. However, very limited information is available for the relative cost-effectiveness of these new treatments. OBJEC-TIVES: To evaluate the cost-effectiveness of graftskin plus standard foot care and becaplermin plus standard foot care in comparison to the standard foot care alone from the societal perspective. METHODS: A decision analysis model was built for chronic diabetic foot ulcer patients. Study period was one year. The effectiveness was measured in quality-adjusted-life years (QALYs). Data for QALYs, transition probabilities, efficacy, and costs were taken mostly from the literature. All costs were adjusted to 2002 US dollars. Sensitivity analyses were performed on important parameters including costs and efficacy of graftskin and becaplermin, and costs of amputation. RESULTS: In the base case analysis, graftskin was a dominant strategy over becaplermin and standard care. Also, becaplermin was the dominant strategy over standard care alone. Compared to the standard care group and the becaplermin group, the graftskin group had higher QALYs (difference was 0.03 and 0.06, respectively). In terms of savings of medical costs, the graftskin group gained $2202 and $179, compared to the standard care group and the becaplermin group during the study period. The results of the sensitivity analysis were consistent with the results of the base case analysis. CON-CLUSIONS: Although the standard care costs less at the initial state, patients receiving the standard care only are more likely to have costly outcomes compared to patients receiving graftskin or becaplermin, and this translates into higher expected costs. Also, results indicate that treating diabetic foot ulcer patients with graftskin was more cost-effective than treating with becaplermin.
